Use of deferasirox across pediatric, geriatric and organ-impairment populations requires individualised dose decisions and tailored monitoring. The summary below captures mainstream guidance - always consult the locally approved prescribing information.
Pediatric Use #
- Approved for transfusional iron overload typically from age 2 years, and for non-transfusion-dependent thalassemia (NTDT) typically from age 6 years (varies by market)
- Dosing is per body weight (mg/kg/day) - the 100 mg and 125 mg dispersible-tablet strengths support fine pediatric titration
- Risk of tubulopathy (Fanconi-like syndrome) is higher in pediatric patients - close renal monitoring is essential
- Growth, sexual development, pubertal staging and endocrine function should be monitored at regular intervals
- Audiology and ophthalmology baseline and annual screening recommended
- Counsel parents/carers on the dispersible-tablet preparation method and the importance of empty-stomach administration
Geriatric Use #
- No upper age limit; safety in elderly drives more cautious initiation and monitoring
- Higher risk of GI hemorrhage / ulceration - particularly in patients on NSAIDs, corticosteroids, oral bisphosphonates or anticoagulants
- Higher risk of acute renal failure (volume depletion, baseline renal dysfunction, polypharmacy)
- Higher risk of hepatic dysfunction
- Cytopenias may be more clinically significant given baseline marrow reserve
- Start at the lower end of the dose range; intensify monitoring
Hepatic Impairment #
| Severity | Recommendation |
|---|---|
| Mild (Child-Pugh A) | No formal dose adjustment; routine monitoring |
| Moderate (Child-Pugh B) | Start at substantially reduced dose (e.g. 50% reduction); intensify LFT monitoring |
| Severe (Child-Pugh C) | Avoid deferasirox |
Discontinue or interrupt therapy if ALT/AST rises persistently > 5x ULN or if features of hepatic decompensation appear.
Renal Impairment #
- Contraindicated when CrCl < 60 mL/min (refer to locally approved label)
- Although deferasirox itself is not eliminated renally to a major extent, renal toxicity has been reported and pre-existing impairment increases risk
- Monitor creatinine weekly in the first month, then monthly
- Persistent creatinine rises > 33% above baseline warrant dose reduction or discontinuation per local labelling
- Avoid concurrent nephrotoxins where possible
Pregnancy & Fertility #
- Use only if clearly necessary; consult specialist obstetric / hematology advice
- Counsel on effective non-hormonal contraception during therapy (deferasirox induces CYP3A4 and may reduce hormonal contraceptive efficacy)
- Animal data show reproductive toxicity at higher exposures; human data are limited
Breast-Feeding #
Excretion of deferasirox in human milk is unknown. A decision to discontinue breast-feeding or treatment should be individualised based on the importance of therapy to the mother and infant safety.
Patients with G6PD Deficiency #
No specific contraindication, but standard caution applies in patients with concomitant hematological conditions; monitor closely.